semaglutide mash approval Receives FDA for Treatment of The FDA just approved semaglutide

This may provide a basis for finding new therapeutic targets for ischemic stroke

Published research indicates that muscle loss and lean mass reduction are common components of weight loss during GLP-1 therapy, but the proportion varies considerably by individual, drug, dose, and - critically - habits

Although contrary to the notion that G6PD-d largely limits proliferative capacity, Varghese et al

Trials on Zepbound found that 0.1% of patients had a severe hypersensitivity reaction (such as anaphylaxis) compared to 0% in the placebo group

Patients should be aware that while the medication is technically available, obtaining it requires a valid prescription from a healthcare provider